A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.

Michael S. Gordon,Robert L. Ilaria,Dinesh P. de Alwis,David S. Mendelson,Scott McKane,Margaret M. Wagner,Katherine Y. Look,Patricia LoRusso

A phase I study of tasisulam sodium (LY573636 sodium), a novel anticancer compound, administered as a 24-h continuous infusion in patients with advanced solid tumors.

2013

Michael S. Gordon
Robert L. Ilaria
Dinesh P. de Alwis
David S. Mendelson
Scott McKane
Margaret M. Wagner
Katherine Y. Look
Patricia LoRusso

Purpose To determine the recommended/maximum tolerated dose (MTD), pharmacokinetics (PK), and safety profile of tasisulam sodium (hereafter tasisulam), a novel anticancer agent.

Keywords:

Pharmacology
Tasisulam Sodium
Maximum tolerated dose
Medicine
LY573636-Sodium
Pharmacokinetics
Regimen
Bone marrow suppression
Neutropenia
Loading dose
Bone marrow
Cohort
Half-life

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations